Three-month outcomes of faricimab loading therapy for wet age-related macular degeneration in Japan
© 2023. The Author(s)..
This multicenter study aimed to assess the short-term effectiveness and safety of faricimab in treatment-naïve patients with wet age-related macular degeneration (wAMD) in Japan. We retrospectively reviewed 63 eyes of 61 patients with wAMD, including types 1, 2, and 3 macular neovascularization as well as polypoidal choroidal vasculopathy (PCV). Patients received three consecutive monthly intravitreal injections of faricimab as loading therapy. Over these 3 months, visual acuity improved gradually compared to baseline. Moreover, the central foveal thickness decreased significantly at 1, 2, and 3 months compared to baseline (p < 0.0001). At 3 months after initiation of faricimab therapy, a dry macula (defined as absence of intraretinal or subretinal fluid) was achieved in 82% of the eyes. Complete regression of polypoidal lesions was observed in 52% of eyes with PCV. Subfoveal choroidal thickness also decreased significantly at 1, 2, and 3 months compared to baseline (p < 0.0001). Although retinal pigment epithelium tears developed in two eyes, there were no other ocular or systemic complications observed during the 3 months of loading therapy. In conclusion, loading therapy using faricimab resulted in improved visual acuity and retinal morphology in Japanese patients with wAMD without particular safety issues.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Scientific reports - 13(2023), 1 vom: 30. Mai, Seite 8747 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mukai, Ryo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Angiogenesis Inhibitors |
|---|
| Anmerkungen: |
Date Completed 01.06.2023 Date Revised 02.06.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41598-023-35759-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357559444 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357559444 | ||
| 003 | DE-627 | ||
| 005 | 20231226210436.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41598-023-35759-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1191.xml |
| 035 | |a (DE-627)NLM357559444 | ||
| 035 | |a (NLM)37253802 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mukai, Ryo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Three-month outcomes of faricimab loading therapy for wet age-related macular degeneration in Japan |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.06.2023 | ||
| 500 | |a Date Revised 02.06.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a This multicenter study aimed to assess the short-term effectiveness and safety of faricimab in treatment-naïve patients with wet age-related macular degeneration (wAMD) in Japan. We retrospectively reviewed 63 eyes of 61 patients with wAMD, including types 1, 2, and 3 macular neovascularization as well as polypoidal choroidal vasculopathy (PCV). Patients received three consecutive monthly intravitreal injections of faricimab as loading therapy. Over these 3 months, visual acuity improved gradually compared to baseline. Moreover, the central foveal thickness decreased significantly at 1, 2, and 3 months compared to baseline (p < 0.0001). At 3 months after initiation of faricimab therapy, a dry macula (defined as absence of intraretinal or subretinal fluid) was achieved in 82% of the eyes. Complete regression of polypoidal lesions was observed in 52% of eyes with PCV. Subfoveal choroidal thickness also decreased significantly at 1, 2, and 3 months compared to baseline (p < 0.0001). Although retinal pigment epithelium tears developed in two eyes, there were no other ocular or systemic complications observed during the 3 months of loading therapy. In conclusion, loading therapy using faricimab resulted in improved visual acuity and retinal morphology in Japanese patients with wAMD without particular safety issues | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Angiogenesis Inhibitors |2 NLM | |
| 650 | 7 | |a faricimab |2 NLM | |
| 700 | 1 | |a Kataoka, Keiko |e verfasserin |4 aut | |
| 700 | 1 | |a Tanaka, Koji |e verfasserin |4 aut | |
| 700 | 1 | |a Miyara, Yasunori |e verfasserin |4 aut | |
| 700 | 1 | |a Maruko, Ichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Nakayama, Makiko |e verfasserin |4 aut | |
| 700 | 1 | |a Watanabe, Yuto |e verfasserin |4 aut | |
| 700 | 1 | |a Yamamoto, Akiko |e verfasserin |4 aut | |
| 700 | 1 | |a Wakatsuki, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Onoe, Hajime |e verfasserin |4 aut | |
| 700 | 1 | |a Wakugawa, Sorako |e verfasserin |4 aut | |
| 700 | 1 | |a Terao, Nobuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Hasegawa, Taiji |e verfasserin |4 aut | |
| 700 | 1 | |a Hashiya, Nozomu |e verfasserin |4 aut | |
| 700 | 1 | |a Kawai, Moeko |e verfasserin |4 aut | |
| 700 | 1 | |a Maruko, Ruka |e verfasserin |4 aut | |
| 700 | 1 | |a Itagaki, Kanako |e verfasserin |4 aut | |
| 700 | 1 | |a Honjo, Jyunichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Okada, Annabelle A |e verfasserin |4 aut | |
| 700 | 1 | |a Mori, Ryusaburo |e verfasserin |4 aut | |
| 700 | 1 | |a Koizumi, Hideki |e verfasserin |4 aut | |
| 700 | 1 | |a Iida, Tomohiro |e verfasserin |4 aut | |
| 700 | 1 | |a Sekiryu, Tetsuju |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Scientific reports |d 2011 |g 13(2023), 1 vom: 30. Mai, Seite 8747 |w (DE-627)NLM215703936 |x 2045-2322 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g number:1 |g day:30 |g month:05 |g pages:8747 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41598-023-35759-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2023 |e 1 |b 30 |c 05 |h 8747 | ||